Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jun 15, 2022; 14(6): 1162-1174
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1162
Published online Jun 15, 2022. doi: 10.4251/wjgo.v14.i6.1162
Table 1 Univariate analyses: Differences between intestinal and diffuse subtypes (Chi-squared and Student’s t tests)
Feature | P value | OR, diffuse (95%CI)1 |
Age | < 0.001 | |
Depth | 0.004 | |
Macroscopic type | 0.001 | |
Polypoid | 0.86 (0.45-1.65) | |
Flat | 3.16 (1.49-6.71) | |
Ulcerative | 1.54 (0.9-2.65) | |
Fungoid | 0.38 (0.21-0.69) | |
Local symptoms | 0.004 | 0.4 (0.2-0.75) |
Necrosis | 0.006 | 0.39 (0.2-0.77) |
Perineural infiltration | < 0.001 | 2.98 (1.78-5) |
Intratumoral inflammation | 0.054 | |
No | 0.63 (0.28-1.38) | |
Mild | 2.08 (1.07-4.03) | |
High | 0.68 (0.38-1.2) | |
Desmoplasia | < 0.001 | 0.29 (0.16-0.54) |
Microsatellite instability | 0.023 | 0.16 (0.02-0.28) |
HERCEPTEST 2+/3+ | 0.018 | 0.07 (0.02-0.24) |
T stage | 0.02 | |
T1 | 0.41 (0.19-0.88) | |
T2 | 0.74 (0.39-1.4) | |
T3 | 1.25 (0.76-2.05) | |
T4 | 2.08 (1.08-3.99) | |
N stage | 0.02 | |
N0 | 0.5 (0.3-0.85) | |
N1 | 0.8 (0.4-1.6) | |
N2 | 1.93 (1.04-3.55) | |
N3 | 1.62 (0.9-2.93) | |
Metastatic lymph nodes | 0.005 | |
Lymph node ratio | < 0.001 | |
Adjuvant therapy | 0.022 | 2.14 (1.11-4.15) |
Recurrence | < 0.001 | 2.63 (1.55-4.47) |
Death | < 0.001 | 2.82 (1.56-5.09) |
Table 2 Multivariate analysis: Variables independently related to Laurén subtypes
Factor | P value | HR | 95%CI for HR1 | |
Lower | Upper | |||
Lymph node ratio | 0.012 | 9.463 | 1.655 | 54.091 |
Depth | 0.037 | 1.108 | 1.006 | 1.220 |
Desmoplasia | 0.014 | 0.323 | 0.131 | 0.798 |
Macroscopy | ||||
Polypoid | 0.011 | |||
Flat | 0.006 | 10.002 | 1.928 | 51.895 |
Ulcerative | 0.027 | 4.536 | 1.189 | 17.307 |
Fungoid | 0.686 | 1.318 | 0.345 | 5.030 |
Table 3 Independent risk factors for tumor recurrence and cancer-specific death in intestinal and diffuse-type gastric cancer
Dependent variable | Factor | P value | HR | 95%CI for HR | |
Lower | Upper | ||||
Intestinal type GC | |||||
Tumor death (OS) | LNR | 0.004 | 32.424 | 3.057 | 343.96 |
Growth | 0.052 | ||||
Expansive | |||||
Infiltrative | 4.678 | 0.987 | 22.177 | ||
Recurrence (DFS) | LNR | 0.03 | 3.758 | 1.138 | 12.411 |
Vascular invasion | 0.005 | 2.829 | 1.379 | 5.806 | |
T stage | 0.056 | ||||
T1-2 | 1 | ||||
T3-4 | 2.193 | 0.98 | 4.909 | ||
Diffuse type GC | |||||
Tumor death (OS) | LNR | 0.026 | 5.729 | 1.234 | 26.599 |
Necrosis | 0.008 | 4.234 | 1.460 | 12.278 | |
Recurrence (DFS) | Size | 0.001 | 1.018 | 1.005 | 1.030 |
LNR | < 0.001 | 11.420 | 3.895 | 33.477 |
Table 4 Prognostic scores for patients with intestinal-type gastric cancer
Dependent variable | Death | Recurrence | ||
Features | Growth | T stage | ||
Expansive | 0 | T1-2 | 0 | |
Infiltrative | 5 | T3-4 | 2 | |
LNR | × 32 | LNR | × 4 | |
Vascular invasion | 3 | |||
Total score | 0-37 | 0-9 | ||
Stages | ||||
S1 | 0 | 0 | ||
S2 | > 0-5 | > 0-2 | ||
S3 | > 5-14 | > 2-< 5 | ||
S4 | > 14 | 5-9 |
Table 5 Prognostic scores for patients with diffuse-type gastric cancer
Dependent variable | Death | Recurrence | |||
Features | Necrosis | 4 | Size in mm | × 1 | |
LNR | × 6 | LNR | × 11 | ||
Total | 0-10 | 0-120 | |||
Stages | |||||
S1 | 0-< 1.5 | 0-20 | |||
S2 | 1.5-4 | > 20-60 | |||
S3 | > 4 | > 60 |
- Citation: Díaz del Arco C, Estrada Muñoz L, Ortega Medina L, Molina Roldán E, Cerón Nieto MÁ, García Gómez de las Heras S, Fernández Aceñero MJ. Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer. World J Gastrointest Oncol 2022; 14(6): 1162-1174
- URL: https://www.wjgnet.com/1948-5204/full/v14/i6/1162.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i6.1162